Clinical-stage pharmaceutical company Cempra, Inc. (CEMP) said Wednesday that it has closed its previously announced initial public offering of 8.4 million shares of common stock at $6.00 per share.
The shares began trading on February 3 on The Nasdaq Global Market under the ticker symbol "CEMP."
Total net proceeds to the company from the offering, after deducting underwriter discounts and commissions and estimated offering expenses, were about $47.7 million.
The company plans to use the net proceeds from the offering to develop two of its product candidates, CEM-101 and Taksta.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org